Cantargia AB is a biopharma company, focused on the development of antibodies for the treatment of cancer. It was formed by Lunds University Bioscience AB (LUBio) and Innovagen AB.
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”CANTA.ST” api=”yf” style=”font-size: 15px”]
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cantargia-ab” connections=”true” suffix=””]
Cantariga focuses on the development of a discovery made by Prof. Thoas Fioretos and Dr Marcus J_rs from Lund University.
who found that leukaemia stem cells express a protein on the surface called IL1RAP, which is not expressed to a large extent
on normal stem cells.
In Feb. 2015, raised Cantargia AB (SSE:CANTA) $5.2 Mn through an IPO offerings, and is listed on Nasdaq Stockholm First North. In 2017 Cantargia raised approx $26 Mn USD through right issue subscription.